

Supporting Information

Catalytic Enantioselective Synthesis of Indolizino[8,7-*b*]indole Alkaloid Derivatives Based on the Tandem Reaction of Tertiary Enamides

Xin-Ming Xu^{a,*}, Ming Xie,^b Jiazhu Li^a, Mei-Xiang Wang^{b,*}

^a College of Chemistry and Chemical Engineering, Yantai University, Yantai 264005, China

^b Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology (Ministry of Education), Department of Chemistry, Tsinghua University, Beijing 100084 China

Email: xin_mingxu@163.com


Table of Contents

1. General Information	3
2. Preparation of Enamides	3
3. Lewis Acid Catalyzed Reaction of 1	7
4. Optimization of Catalytic Enantioselective Reaction Conditions	11
5. Synthesis of Enantioenriched Indolizino[8,7- <i>b</i>]indole Derivatives	13
6. Synthesis of 3 , 4 and 5	31
7. The X-ray data of compounds 2b	37
8. References	37
9. Copies of ^1H NMR and ^{13}C NMR Spectra of Products	38

1. General information

All chemicals were dried or purified according to standard procedures prior to use. Flash column chromatography was performed on silica gel (100-200). Reactions were monitored using pre-coated, glass-backed silica gel plates and visualized by means of UV irradiation (254 nm) or KMnO₄, phosphomolybdic acid, ninhydrine, pancaldi, and *p*-anisaldehyde vanillin. ¹H NMR and ¹³C NMR spectra were recorded using 400 MHz spectrometers at ambient temperature. ¹H frequency is at 400.13 MHz and ¹³C frequency is at 100.62 MHz. Chemical shifts are reported in ppm with either tetramethylsilane or the residual solvent resonance used as an internal standard. Abbreviations are used in the description of NMR data as follows: chemical shift (δ , ppm), multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet), coupling constant (J , Hz). Infrared spectra were recorded using a FT-IR spectrometer with KBr discs in the 4000-400 cm⁻¹ region. Mass spectra was measured using mass spectrometers. All yields reported were isolated yields and ee values were determined by HPLC using Daicel ASH or ODH chiral columns eluted with a mixture of isopropanol and hexane at 25 °C.

2. Preparation of Tertiary Enamides



Step 1. The toluene solution of tryptamine (0.5 M) and ketone (0.5 M) was vigorously stirred with Dean-stark at reflux until the conversion of amine to imine was completed. The mixture was concentrated in vacuo to give a crude imine product which was used immediately without further purification.

Step 2. Under argon atmosphere, imine (5 mmol) was dissolved in DMF (10 mL), and then Et₃N (6 mmol) was added. After cooling to -40 °C, acyl chloride (6

mmol) was added dropwise during 20 min. The resulting mixture was kept stirring at -40°C for another 30 min. A saturated aqueous NaHCO₃ solution (20 mL) was added to quench the reaction. The mixture was extracted with ethyl acetate (3 × 50 mL), and washed with brine (2 × 50 mL). The organic layer was dried over anhydrous Na₂SO₄, and concentrated under vacuum. The residue was chromatographed on a silica gel column eluted with a mixture of petroleum ether/ethyl acetate (5:1) to give a pure enamide product **1**. The structure of tertiary enamides was fully characterized and the characterization data are listed below.

N-(2-(1*H*-indol-3-yl)ethyl)-2-oxo-2-phenyl-N-(1-phenylvinyl)acetamide (1a)

White solid (63% yield, 2 steps). m.p. 102-103 °C; IR (KBr) ν 3399, 1678, 1646, 1626, 1416, 1235, 1205 cm⁻¹; ¹H NMR (400MHz, CDCl₃, TMS) δ (ppm) 8.14 (s, 1H), 7.82 (d, *J* = 7.4Hz, 2H), 7.58-7.48 (m, 4H), 7.43-7.33 (m, 6H), 7.17 (t, *J* = 7.6 Hz, 1H), 7.07 (t, *J* = 7.6 Hz, 2H), 5.22 (s, 1H), 4.83 (s, 1H), 3.91 (t, *J* = 7.6 Hz, 2H), 3.10 (t, *J* = 7.6 Hz, 2H); ¹³C NMR (100MHz, CDCl₃, TMS) δ (ppm) 190.4, 167.3, 145.8, 136.2, 134.7, 134.3, 134.0, 129.71, 129.67, 128.89, 128.86, 127.6, 127.4, 122.4, 122.2, 119.5, 118.8, 114.3, 112.3, 111.2, 45.1, 23.3; HRMS (ESI) Calcd. for C₂₆H₂₃N₂O₂, [M+H]⁺ 395.1754. Found: 395.1751.

N-(2-(1*H*-indol-3-yl)ethyl)-N-(1-(4-bromophenyl)vinyl)-2-oxo-2-phenylacetamide (1b)

White solid (66% yield, 2 steps). m.p. 144-146 °C; IR (KBr) ν 3431, 1678, 1648, 1628, 1421 cm⁻¹; ¹H NMR (400MHz, CDCl₃, TMS) δ (ppm) 10.10 (s, 1H), 7.85 (d, *J* = 8.2 Hz, 2H), 7.67 (t, *J* = 7.3 Hz, 1H), 7.60 (d, *J* = 8.2 Hz, 2H), 7.54-7.49 (m, 5H), 7.42 (d, *J* = 7.8 Hz, 1H), 7.11 (t, *J* = 7.6 Hz, 1H), 7.00 (t, *J* = 7.6 Hz, 1H), 5.39 (s, 1H), 4.95 (s, 1H), 3.89 (t, *J* = 7.6 Hz, 2H), 3.13 (t, *J* = 7.6 Hz, 2H); ¹³C NMR (100MHz, CDCl₃, TMS) δ (ppm) 191.2, 167.7, 145.6, 137.7, 135.15, 135.09, 134.8, 132.6, 130.2, 130.1, 129.8, 128.5, 123.9, 123.8, 122.2, 119.5, 119.3, 115.6, 112.2, 112.1, 45.7, 24.0; HRMS (ESI) Calcd. for C₂₆H₂₂N₂O₂Br, [M+H]⁺ 473.0859. Found: 473.0858.

N-(2-(1*H*-indol-3-yl)ethyl)-N-(1-(4-fluorophenyl)vinyl)-2-oxo-2-phenylacetamide (1c)

White solid (62% yield, 2 steps). m.p. 116-118 °C; IR (KBr) ν 3409, 3056, 2933, 1680, 1651, 1599, 1506 cm⁻¹; ¹H NMR (400MHz, ACETONE-D₆, TMS) δ (ppm) 10.11 (s, 1H), 7.87-7.85 (m, 2H), 7.70-7.65 (m, 1H), 7.64-7.59 (m, 2H), 7.55-7.51 (m, 3H), 7.43-7.40 (m, 1H), 7.25-7.16 (m, 3H), 7.13-7.08 (m, 1H), 7.02-6.98 (m, 1H), 5.32 (s, 1H), 4.92 (s, 1H), 3.88 (t, J = 7.2 Hz, 2H), 3.12 (t, J = 7.6 Hz, 2H); ¹⁹F NMR (376MHz, DMSO-d₆) δ (ppm) -113.41 (t, J = 6.0 Hz); ¹³C NMR (100MHz, ACETONE-D₆, TMS) δ (ppm) 191.2, 167.7, 164.2 (d, J = 246 Hz, 1C), 145.7, 137.6, 135.1, 134.9, 132.2 (d, J = 2.9 Hz, 1C), 130.4 (d, J = 8.6 Hz, 1C), 130.2, 129.7, 128.5, 123.8, 122.2, 119.5, 119.2, 116.3 (d, J = 21.9 Hz, 1C), 114.8, 112.2, 112.1, 45.6, 24.0; HRMS (ESI) Calcd. for C₂₆H₂₁N₂O₂FNa, [M+Na]⁺ 435.1479. Found: 435.1477.

N-(2-(1*H*-indol-3-yl)ethyl)-N-(1-(4-chlorophenyl)vinyl)-2-oxo-2-phenylacetamid e (1d)

White solid (72% yield, 2 steps). m.p. 140-142 °C; IR (KBr) ν 3412, 2930, 1679, 1650, 1488, 1235, 1203 cm⁻¹; ¹H NMR (400MHz, ACETONE-D₆, TMS) δ (ppm) 10.11 (s, 1H), 7.86-7.84 (m, 2H), 7.69-7.64 (m, 1H), 7.59-7.49 (m, 5H), 7.46-7.41 (m, 3H), 7.24 (d, J = 2.4Hz, 1H), 7.13-7.09 (m, 1H), 7.02-6.98 (m, 1H), 5.38 (s, 1H), 4.95 (s, 1H), 3.89 (t, J = 7.2 Hz, 2H), 3.12 (t, J = 7.6 Hz, 2H); ¹³C NMR (100MHz, ACETONE-D₆, TMS) δ (ppm) 191.2, 167.7, 145.4, 137.6, 135.6, 135.1, 134.8, 134.6, 130.2, 129.8, 129.7, 129.5, 128.5, 123.8, 122.2, 119.5, 119.2, 115.5, 112.2, 112.1, 45.7, 24.0; HRMS (ESI) Calcd. for C₂₆H₂₁N₂O₂ClNa, [M+Na]⁺ 451.1184. Found: 451.1186.

N-(2-(1*H*-indol-3-yl)ethyl)-N-(1-(4-nitrophenyl)vinyl)-2-oxo-2-phenylacetamide (1e)

White solid (79% yield, 2 steps). m.p. 145-147 °C; IR (KBr) ν 3337, 3060, 2940, 1682, 1646, 1595, 1519, 1426 cm⁻¹; ¹H NMR (400MHz, CDCl₃, TMS) δ (ppm) 8.21-8.17 (m, 3H), 7.84-7.81 (m, 2H), 7.66-7.58 (m, 3H), 7.50 (d, J = 8.0 Hz, 1H), 7.46-7.42 (m, 2H), 7.37 (d, J = 8.4 Hz, 1H), 7.21-7.17 (m, 1H), 7.10-7.06 (m, 2H), 5.34 (d, J = 0.8 Hz, 1H), 4.98 (d, J = 0.8 Hz, 1H), 3.90 (t, J = 7.2 Hz, 2H), 3.13 (t, J = 7.2 Hz, 2H); ¹³C NMR (100MHz, ACETONE-D₆, TMS) δ (ppm) 191.2, 167.6,

149.1, 144.8, 142.1, 137.6, 135.3, 134.6, 130.3, 129.8, 129.2, 128.5, 124.5, 123.9, 122.2, 119.5, 119.2, 118.4, 112.2, 112.0, 45.9, 24.0; HRMS (ESI) Calcd. for C₂₆H₂₁N₃O₄Na, [M+Na]⁺ 462.1424. Found: 462.1423.

N-(2-(1*H*-indol-3-yl)ethyl)-N-(1-(3-bromophenyl)vinyl)-2-oxo-2-phenylacetamide (1f)

White solid (59% yield, 2 steps). m.p. 155-157 °C; IR (KBr) ν 3341, 1670, 1654, 1420, 1238, 1199 cm⁻¹; ¹H NMR (400MHz, CDCl₃, TMS) δ (ppm) 8.10 (s, 1H), 7.81 (d, *J* = 7.8Hz, 2H), 7.62-7.35 (m, 8H), 7.24 (t, *J* = 7.8 Hz, 1H), 7.19 (t, *J* = 7.8 Hz, 1H), 7.09 (t, *J* = 7.1 Hz, 2H), 5.21 (s, 1H), 4.85 (s, 1H), 3.90 (t, *J* = 7.6 Hz, 2H), 3.10 (t, *J* = 7.6 Hz, 2H); ¹³C NMR (100MHz, CDCl₃, TMS) δ (ppm) 190.3, 167.2, 144.6, 137.0, 136.3, 134.4, 133.8, 132.6, 130.38, 130.36, 129.6, 129.1, 128.9, 127.5, 126.0, 123.0, 122.5, 122.2, 119.6, 118.8, 115.3, 112.1, 111.3, 45.2, 23.3; HRMS (ESI) Calcd. for C₂₆H₂₂N₂O₂Br, [M+H]⁺ 473.0859. Found: 473.0854.

N-(2-(1*H*-indol-3-yl)ethyl)-N-(1-(3-methoxyphenyl)vinyl)-2-oxo-2-phenylacetamide (1g)

White solid (46% yield, 2 steps). m.p. 109-111 °C; IR (KBr) ν 3345, 3047, 2947, 1674, 1651, 1597, 1425, 1237 cm⁻¹; ¹H NMR (400MHz, ACETONE-D₆, TMS) δ (ppm) 10.08 (s, 1H), 7.85-7.83 (m, 2H), 7.66-7.63 (m, 1H), 7.50 (t, *J* = 7.6 Hz, 3H), 7.40-7.29 (m, 2H), 7.22 (d, *J* = 2.4 Hz, 1H), 7.14-7.04 (m, 3H), 7.00-6.91 (m, 2H), 5.33 (s, 1H), 4.91 (s, 1H), 3.88 (t, *J* = 7.6 Hz, 2H), 3.10 (t, *J* = 8.0 Hz, 2H); ¹³C NMR (100MHz, ACETONE-D₆, TMS) δ (ppm) 191.2, 167.7, 160.8, 146.4, 137.6, 137.3, 135.0, 134.9, 130.5, 130.2, 129.7, 128.5, 126.5, 123.7, 122.2, 120.4, 119.5, 119.3, 115.9, 114.9, 113.5, 112.2, 55.6, 45.7, 24.0; HRMS (ESI) Calcd. for C₂₇H₂₄N₂O₃Na, [M+Na]⁺ 447.1679. Found: 447.1676.

N-(2-(1*H*-indol-3-yl)ethyl)-2-(3-bromophenyl)-N-(1-(4-bromophenyl)vinyl)-2-oxoacetamide (1h)

White solid (68% yield, 2 steps). m.p. 145-147 °C; IR (KBr) ν 3417, 1683, 1644, 1634, 1419, 1226, 1198 cm⁻¹; ¹H NMR (400MHz, CDCl₃, TMS) δ (ppm) 8.10 (s, 1H), 7.97 (s, 1H), 7.70 (d, *J* = 7.8 Hz, 2H), 7.50 (t, *J* = 7.3 Hz, 3H), 7.36 (t, *J* = 8.7 Hz, 3H), 7.29 (t, *J* = 7.8 Hz, 1H), 7.19 (t, *J* = 7.6 Hz, 1H), 7.13-7.07 (m, 2H), 5.18 (s,

1H), 4.73 (s, 1H), 3.90 (t, J = 7.3 Hz, 2H), 3.09 (t, J = 7.3 Hz, 2H); ^{13}C NMR (100MHz, CDCl_3 , TMS) δ (ppm) 188.8, 166.6, 144.9, 137.2, 136.3, 135.6, 133.6, 132.3, 132.1, 132.0, 130.5, 129.0, 128.2, 127.6, 124.1, 123.2, 122.3, 119.6, 118.8, 114.8, 112.1, 111.4, 45.0, 23.3; HRMS (ESI) Calcd. for $\text{C}_{26}\text{H}_{21}\text{N}_2\text{O}_2\text{Br}_2$, $[\text{M}+\text{H}]^+$ 552.9944. Found: 552.9941.

***N*-(2-(1*H*-indol-3-yl)ethyl)-2-(4-bromophenyl)-*N*-(1-(4-bromophenyl)vinyl)-2-oxoacetamide (**1i**)**

White solid (66% yield, 2 steps). m.p. 159-160 °C; IR (KBr) ν 3344, 1687, 1650, 1582, 1397, 1220, 1203 cm^{-1} ; ^1H NMR (400MHz, CDCl_3 , TMS) δ (ppm) 8.10 (s, 1H), 7.62 (d, J = 8.7 Hz, 2H), 7.55-7.50 (m, 5H), 7.38-7.35 (m, 3H), 7.20 (t, J = 7.6 Hz, 1H), 7.11-7.08 (m, 2H), 5.20 (s, 1H), 4.76 (s, 1H), 3.88 (t, J = 7.3 Hz, 2H), 3.08 (t, J = 7.4 Hz, 2H); ^{13}C NMR (100MHz, CDCl_3 , TMS) δ (ppm) 189.2, 166.8, 145.0, 136.2, 133.6, 132.7, 132.3, 132.1, 131.0, 129.8, 129.0, 127.5, 124.1, 122.5, 122.4, 119.7, 118.8, 114.7, 112.1, 111.3, 45.1, 23.3; HRMS (ESI) Calcd. For $\text{C}_{26}\text{H}_{21}\text{N}_2\text{O}_2\text{Br}_2$, $[\text{M}+\text{H}]^+$ 552.9944. Found: 552.9942.

***N*-(2-(1*H*-indol-3-yl)ethyl)-*N*-(1-(4-bromophenyl)vinyl)-2-oxo-2-(p-tolyl)acetamide (**1j**)**

White solid (54% yield, 2 steps). m.p. 173-175 °C; IR (KBr) ν 3347, 1680, 1647, 1635, 1603, 1425, 1225 cm^{-1} ; ^1H NMR (400MHz, CDCl_3 , TMS) δ (ppm) 10.10 (s, 1H), 7.75 (d, J = 8.2 Hz, 2H), 7.61-7.58 (m, 2H), 7.51 (t, J = 8.7 Hz, 3H), 7.41 (d, J = 8.2 Hz, 1H), 7.33 (d, J = 8.2 Hz, 2H), 7.24 (d, J = 2.3 Hz, 1H), 7.10 (t, J = 7.3 Hz, 1H), 7.00 (t, J = 7.3 Hz, 1H), 5.38 (s, 1H), 4.95 (s, 1H), 3.87 (t, J = 7.6 Hz, 2H), 3.11 (t, J = 7.6 Hz, 2H), 2.41 (s, 3H); ^{13}C NMR (100MHz, CDCl_3 , TMS) δ (ppm) 190.9, 167.9, 146.2, 145.6, 137.7, 135.2, 132.6, 132.5, 130.4, 130.1, 128.5, 123.9, 123.8, 122.2, 119.5, 119.3, 115.6, 112.2, 112.1, 45.6, 24.0, 21.7; HRMS (ESI) Calcd. For $\text{C}_{27}\text{H}_{24}\text{N}_2\text{O}_2\text{Br}$, $[\text{M}+\text{H}]^+$ 487.1016. Found: 487.1013.

***N*-(1-(4-bromophenyl)vinyl)-*N*-(2-(5-chloro-1*H*-indol-3-yl)ethyl)-2-oxo-2-phenylacetamide (**1k**)**

White solid (62% yield, 2 steps). m.p. 158-159 °C; IR (KBr) ν 3420, 1686, 1632, 1448, 1424, 1230, 1204 cm^{-1} ; ^1H NMR (400MHz, CDCl_3 , TMS) δ (ppm) 8.19 (s,

1H), 7.83 (d, $J = 6.9$ Hz, 2H), 7.59 (t, $J = 7.3$ Hz, 1H), 7.51 (d, $J = 8.2$ Hz, 2H), 7.46-7.36 (m, 5H), 7.27-7.25 (m, 1H), 7.14 (d, $J = 1.8$ Hz, 1H), 7.12-7.11 (m, 1H), 5.18 (s, 1H), 4.80 (s, 1H), 3.85 (t, $J = 7.6$ Hz, 2H), 3.05 (t, $J = 7.6$ Hz, 2H); ^{13}C NMR (100MHz, CDCl_3 , TMS) δ (ppm) 190.3, 167.3, 145.0, 134.6, 134.5, 133.9, 133.6, 132.1, 129.7, 129.0, 128.7, 125.4, 124.2, 123.8, 122.6, 118.3, 114.7, 112.3, 112.1, 45.0, 23.2; HRMS (ESI) Calcd. For $\text{C}_{26}\text{H}_{21}\text{N}_2\text{O}_2\text{ClBr}$, $[\text{M}+\text{H}]^+$ 507.0469. Found: 507.0466.

N-(1-(4-bromophenyl)vinyl)-N-(2-(5-methyl-1*H*-indol-3-yl)ethyl)-2-oxo-2-phenyl acetamide (1l)

White solid (70% yield, 2 steps). m.p. 133-135 °C; IR (KBr) ν 3430, 2942, 1687, 1633, 1424, 1232 cm^{-1} ; ^1H NMR (400MHz, ACETONE-D₆, TMS) δ (ppm) 9.95 (s, 1H), 7.89-7.87 (m, 2H), 7.70-7.66 (m, 1H), 7.62-7.59 (m, 2H), 7.56-7.49 (m, 4H), 7.28 (d, $J = 8.4$ Hz, 1H), 7.21-7.18 (m, 2H), 6.94-6.92 (m, 1H), 5.37 (s, 1H), 4.96 (s, 1H), 3.86 (t, $J = 8.0$ Hz, 2H), 3.09 (t, $J = 7.6$ Hz, 2H), 2.36 (s, 1H); ^{13}C NMR (100MHz, CDCl_3 , TMS) δ (ppm) 191.2, 167.7, 145.6, 136.0, 135.1, 134.8, 132.6, 130.2, 130.1, 129.7, 128.7, 128.2, 123.9, 123.86, 123.80, 118.8, 115.4, 111.9, 111.5, 45.6, 24.0, 21.6; HRMS (ESI) Calcd. For $\text{C}_{27}\text{H}_{23}\text{N}_2\text{O}_2\text{BrNa}$, $[\text{M}+\text{Na}]^+$ 509.0835. Found: 509.0834.


N-(1-(4-bromophenyl)vinyl)-N-(2-(5-methoxy-1*H*-indol-3-yl)ethyl)-2-oxo-2-phenylacetamide (1m)

White solid (77% yield, 2 steps). m.p. 143-144 °C; IR (KBr) ν 3308, 1683, 1640, 1626, 1488, 1218, 1207 cm^{-1} ; ^1H NMR (400MHz, CDCl_3 , TMS) δ (ppm) 8.04 (s, 1H), 7.84 (d, $J = 8.7$ Hz, 2H), 7.58 (t, $J = 7.4$ Hz, 1H), 7.49 (d, $J = 6.9$ Hz, 2H), 7.43 (t, $J = 7.8$ Hz, 2H), 7.36 (d, $J = 6.9$ Hz, 2H), 7.23 (d, $J = 8.7$ Hz, 1H), 7.04 (d, $J = 2.3$ Hz, 1H), 6.90 (d, $J = 2.3$ Hz, 1H), 6.85-6.83 (m, 1H), 5.20 (s, 1H), 4.85 (s, 1H), 3.87 (t, $J = 7.8$ Hz, 2H), 3.78 (s, 3H), 3.06 (t, $J = 7.6$ Hz, 2H); ^{13}C NMR (100MHz, CDCl_3 , TMS) δ (ppm) 190.4, 167.3, 154.1, 145.0, 134.5, 133.9, 133.7, 132.0, 131.4, 129.7, 128.99, 128.97, 127.9, 124.0, 123.2, 114.7, 112.6, 112.1, 111.8, 100.4, 56.0, 45.0, 23.5; HRMS (ESI) Calcd. For $\text{C}_{27}\text{H}_{24}\text{N}_2\text{O}_3\text{Br}$, $[\text{M}+\text{H}]^+$ 503.0965. Found: 503.0962.

3. Lewis Acid-Catalyzed Reaction of 1

3.1 Optimization of Reaction Conditions

Table S1. Lewis acid catalyzed reaction of **1b**




Entry	Cat. (equiv)	solvent	T (°C)	t (h)	yield(%) ^b
1	Cu(OTf) ₂ (0.2)	DCM	rt	0.5	69
2	Sn(OTf) ₂ (0.2)	DCM	rt	0.5	91
3	Zn(OTf) ₂ (0.2)	DCM	rt	0.5	98
4	Sc(OTf) ₃ (0.2)	DCM	rt	0.5	99
5	Sc(OTf) ₃ (0.2)	CHCl ₃	rt	0.5	86
6	Sc(OTf) ₃ (0.2)	CH ₃ CN	rt	0.5	96
7	Sc(OTf) ₃ (0.2)	Toluene	rt	0.5	99
8	Sc(OTf) ₃ (0.05)	DCM	rt	0.5	97
9	Sc(OTf) ₃ (0.02)	DCM	rt	0.5	98
10	Sc(OTf) ₃ (0.004)	DCM	rt	2	84
11	Sc(OTf) ₃ (0.001)	DCM	rt	24	mess
12	--	DCM	rt	24	mess

^a A mixture of **1** (0.5 mmol) and catalyst in dry solvent (5 mL) was stirred under argon protection. ^b Isolated yield.

3.2 Synthesis of Racemic Products 2

Table S2. Lewis Acid Catalyzed Reaction of **1**



3.3 General Procedure for the Synthesis of Racemic Products 2

To a flask (10 mL) equipped with a magnetic stirrer was added **1** (0.5 mmol), Sc(OTf)₃ catalyst (2 mol%) and dry CH₂Cl₂ (5 mL) under argon protection. The reaction mixture was stirred at room temperature for 0.5 h and then saturated NaHCO₃ aqueous solution (10 mL) was added to quench the reaction. The mixture was extracted with DCM (3×10 mL), and combined organic layer was washed with brine (2×20 mL) and dried over anhydrous Na₂SO₄. The solvents were removed in *vacuo*

and the residue was purified by flash column chromatography (PE:EA = 2:1) to afford products **2**.

4. Optimization of Catalytic Enantioselective Reaction Conditions




Table S3. Optimization of the reaction catalyzed by different chiral catalyst

Entry	Cat. (0.2 equiv)	Solvent	T (°C)	t (h)	yield ^[b] (%)	ee ^[c] (%)
1	Cat-1	DCM	35	2	95	9
2	Cat-2	DCM	35	2	98	83
3	Cat-3	DCM	35	10	76	58
4	Cat-4	DCM	35	12	mess	n.d. ^[d]
5	L1/Ti(OiPr)₄	DCM	35	2	72	45
6	L2/Cu(OTf)₂	DCM	35	4	88	-82
7	L3/Cu(OTf)₂	DCM	35	48	n.d. ^[d]	0
8	L4/Cu(OTf)₂	DCM	35	48	n.d. ^[d]	-55
9	L5/Cu(OTf)₂	DCM	35	2	94	86
10	L6/Cu(OTf)₂	DCM	35	12	n.d. ^[d]	6
11	L7/Cu(OTf)₂	DCM	35	10	83	80

^a A mixture of **1b** (0.2 mmol) and catalyst (20 mol%) in dry solvent (5 mL) was stirred at 35 °C under argon protection. ^b Isolated yield. ^c Measured by chiral-phase HPLC. ^d Not determined.




Figure S1. The structure of chiral catalyst

Table S4. Optimization of reaction temperature, solvent, and additive

Entry	Cat. (0.2 equiv)	Additive (2.0 equiv)	Solvent	T (°C)	t (h)	yield ^[b] (%)	ee ^[c] (%)
1	L5/Cu(OTf)₂	--	DCM	rt	10	83	80
2	L5/Cu(OTf)₂	--	DCM	0	14	76	77
3	L5/Cu(OTf)₂	HFIP	DCM	35	2	90	83
4	L5/Cu(OTf)₂	--	toluene	rt	12	93	84
5	L5/Cu(OTf)₂	--	toluene	35	10	90	87
6	L5/Cu(OTf)₂	--	toluene	50	8	88	89
7	L5/Cu(OTf)₂	--	toluene	65	3	86	89
8	L5/Cu(OTf)₂	--	toluene	80	1	90	87

^a A mixture of **1b** (0.2 mmol), catalyst (20 mol%) or additive in dry solvent (5 mL) was stirred at different temperature under argon protection.

^b Isolated yield. ^c Measured by HPLC.

Table S5. Optimization of reaction temperature, solvent, and additive

Entry	Cat. (0.2 equiv)	Additive (equiv)	Solvent	T (°C)	t (h)	yield ^[b] (%)	ee ^[c] (%)
1	L5/Cu(OTf)2	--	DCE	50	1	89	76
2	L5/Cu(OTf)2	--	p-Xylene	50	10	89	88
3	L5/Cu(OTf)2	--	Benzene*	50	10	88	91
4	L5/Cu(OTf)2	H ₂ O (1.0)	Benzene	50	10	77	89
5	L5/Cu(OTf)2	H ₂ O (2.0)	Benzene	50	10	76	94
6	L5/Cu(OTf)2	Saturated with H ₂ O	Benzene	50	10	82	97
7	L5/Cu(OTf)2	HFIP (2.0)	Benzene	50	6	80	94
8	L5/Cu(OTf)2	--	Benzene	50	10	88	98

^a A mixture of **1b** (0.2 mmol), catalyst (20 mol%) or additive in dry solvent (5 mL) was stirred at different temperature under argon protection. ^b Isolated yield.

^c Measured by HPLC.

5. Synthesis of Enantioenriched Pyrrolo[2,1-*a*]isoquinoline Derivatives

5.1. General procedure for catalytic enantioselective reaction of tertiary enamides


Under argon protection, a mixture of Cu(OTf)₂ (14.5 mg, 0.04 mmol) and 2,6-*bis*((4*R*,5*S*)-4,5-diphenyl-4,5-dihydrooxazol-2-yl)pyridine (21.0 mg, 0.04 mmol) in dry benzene (3 mL) was stirred at 50 °C for 2 h to give a light blue solution of Cu-Pybox complex. A solution of tertiary enamide **1** (0.2 mmol) in dry benzene (2 mL) was added through a syringe. After stirring for 10 h, the reaction was quenched by adding an aqueous NaHCO₃ solution (5%, 10 mL). The mixture was then extracted with CH₂Cl₂ (3×10 mL), and combined organic layer was washed with brine (2 × 20 mL). The organic layer was dried over anhydrous Na₂SO₄ and concentrated under vacuum. The residue was chromatographed on a silica gel column eluted with a mixture of petroleum ether and ethyl acetate (2:1) to give pure product **2**.

5.3 Characterization Data of Products

(2*S*,11*b**S*)-2-hydroxy-2,11*b*-diphenyl-1,2,5,6,11,11*b*-hexahydro-3*H*-indolizino[8,7-*b*]indol-3-one (**2a**)

White solid (68 mg, 86% yield). m.p. 150-152 °C; $[\alpha]_{25}^D = 112.7^\circ$ ($c = 0.5$, CHCl₃); ee = 97% (DAICEL Chiraldapak AS-H, hexane/2-propanol = 70/30, $\lambda = 254$ nm, flow rate = 0.5 mL/min); IR (KBr) ν 3297, 1679, 1655, 1445 cm⁻¹; ¹H NMR (400MHz, DMSO-*d*₆, TMS) δ (ppm) 11.45 (s, 1H), 7.44-7.39 (m, 4H), 7.34-7.23 (m, 8H), 7.13 (t, $J = 7.6$ Hz, 1H), 7.01 (t, $J = 7.3$ Hz, 1H), 6.03 (s, 1H), 4.31-4.28 (m, 1H), 3.16 (d, $J = 14.2$ Hz, 1H), 3.04-2.98 (m, 1H), 2.95-2.88 (m, 1H), 2.76-2.67 (m, 2H); ¹³C NMR (100MHz, DMSO-*d*₆, TMS) δ (ppm) 174.6, 144.0, 143.7, 136.3, 136.1, 128.6, 128.0, 127.4, 127.2, 126.3, 125.9, 125.8, 121.4, 118.8, 118.1, 111.3, 106.3, 78.2, 62.8, 51.8, 36.3, 19.9; HRMS (ESI) Calcd. for C₂₆H₂₁N₂O₂, [M-H]⁺ 393.1608. Found: 393.1602.

Chiral HPLC analysis of racemic **2a**.




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	11.714	10352770	211176	50.015	75.581
2	24.191	10346369	68226	49.985	24.419
Total		20699139	279402	100.000	100.000

Chiral HPLC analysis of **2a** from asymmetric reaction.




PeakTable

PDA Ch1 254nm 4nm					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	11.649	8192379	169126	98.430	99.065
2	24.015	130688	1596	1.570	0.935
Total		8323068	170723	100.000	100.000


(2*S*,11*bS*)-11*b*-(4-bromophenyl)-2-hydroxy-2-phenyl-1,2,5,6,11,11*b*-hexahydro-3*H*-indolizino[8,7-*b*]indol-3-one (2b)**

White solid (83 mg, 88% yield). m.p. 161-162 °C; $[\alpha]_{25}^D = 164.0^\circ$ ($c = 0.5$, CHCl₃); ee = 99% (DAICEL Chiralpak AS-H, hexane/2-propanol = 70/30, $\lambda = 254$ nm, flow rate = 0.5 mL/min); IR (KBr) ν 3303, 1682, 1489, 1446, 1425, 1396 cm⁻¹; ¹H NMR (400MHz, DMSO-*d*₆, TMS) δ (ppm) 11.46 (s, 1H), 7.52 (d, *J* = 8.7 Hz, 1H), 7.44-7.39 (m, 4H), 7.33 (t, *J* = 7.6 Hz, 2H), 7.28-7.25 (m, 3H), 7.13 (t, *J* = 7.6 Hz, 1H), 7.02 (t, *J* = 7.6 Hz, 1H), 6.05 (s, 1H), 3.14 (d, *J* = 14.2 Hz, 1H), 3.04-2.97 (m, 1H), 2.94-2.85 (m, 1H), 2.70 (d, *J* = 14.7 Hz, 2H); ¹³C NMR (100MHz, DMSO-*d*₆, TMS) δ (ppm) 174.7, 143.5, 143.4, 136.1, 135.7, 131.5, 128.2, 128.0, 127.3, 126.3, 125.8, 121.5, 120.7, 118.8, 118.1, 111.4, 106.5, 78.2, 62.5, 51.5, 36.3, 19.9; HRMS (ESI) Calcd. for C₂₆H₂₀N₂O₂Br, [M-H]⁺ 471.0713. Found: 471.0705.

Chiral HPLC analysis of racemic **2b**.



Chiral HPLC analysis of **2b** from asymmetric reaction.




(2S,11bS)-11b-(4-fluorophenyl)-2-hydroxy-2-phenyl-1,2,5,6,11,11b-hexahydro-3H-indolizino[8,7-b]indol-3-one (2c)


White solid (78 mg, 94% yield). m.p. 165-167 °C; $[\alpha]_{25}^D = 109.3^\circ$ ($c = 0.5$, CHCl₃); ee = 97% (DAICEL Chiraldpak AS-H, hexane/2-propanol = 70/30, $\lambda = 254$ nm, flow rate = 0.5 mL/min); IR (KBr) ν 3290, 3053, 2940, 1653, 1509, 1446, 1233 cm⁻¹; ¹H NMR (400MHz, DMSO-*d*₆, TMS) δ (ppm) 11.45 (s, 1H), 7.44-7.39 (m, 4H), 7.35-7.24 (m, 5H), 7.17-7.11 (m, 3H), 7.02 (t, $J = 7.2$ Hz, 1H), 6.05 (d, $J = 5.2$ Hz, 1H), 4.31-4.28

(m, 1H), 3.17-3.12 (m, 1H), 3.04-2.87 (m, 2H), 2.75-2.68 (m, 2H); ^{19}F NMR (376MHz, DMSO- d_6) δ (ppm) -115.12 (d, $J = 0.54$ Hz); ^{13}C NMR (100MHz, DMSO- d_6 , TMS) δ (ppm) 174.7, 161.2 (d, $J = 243$ Hz, 1C), 143.6, 140.1, 136.1 (d, $J = 4.8$ Hz, 1C), 128.1 (d, $J = 8.6$ Hz, 1C), 128.0, 127.3, 126.3, 125.8, 121.5, 118.8, 118.1, 115.3 (d, $J = 21.9$ Hz, 1C), 111.3, 106.4, 78.2, 62.4, 51.7, 36.2, 19.9; HRMS (ESI) Calcd. for $\text{C}_{26}\text{H}_{21}\text{N}_2\text{O}_2\text{FNa}$, $[\text{M}+\text{Na}]^+$ 435.1479. Found: 435.1477.

Chiral HPLC analysis of racemic **2c**.




Chiral HPLC analysis of **2c** from asymmetric reaction.



(2*S*,11*bS*)-11*b*-(4-chlorophenyl)-2-hydroxy-2-phenyl-1,2,5,6,11,11*b*-hexahydro-3*H*-indolizino[8,7-*b*]indol-3-one (**2d**)**


White solid (79 mg, 92% yield). m.p. 161-163 °C; $[\alpha]_{25}^D = 144.0^\circ$ ($c = 0.5$, CHCl₃); ee = 96% (DAICEL Chiralpak AS-H, hexane/2-propanol = 70/30, $\lambda = 254$ nm, flow rate = 0.5 mL/min); IR (KBr) ν 3303, 3053, 2938, 2851, 1651, 1492, 1446, 1432 cm⁻¹; ¹H NMR (400MHz, CDCl₃, TMS) δ (ppm) 8.17 (s, 1H), 7.52 (d, $J = 8.0$ Hz, 1H), 7.47-7.45 (m, 2H), 7.38- 7.29 (m, 4H), 7.25-7.21 (m, 1H), 7.19-7.14 (m, 3H), 7.04-7.01 (m, 2H), 4.46-4.41 (m, 1H), 3.19-3.00 (m, 3H), 2.97 (d, $J = 14.0$ Hz, 1H), 2.78-2.73 (m, 1H); ¹³C NMR (100MHz, CDCl₃, TMS) δ (ppm) 174.8, 142.5, 141.4, 136.4, 134.5, 134.2, 128.9, 128.4, 128.3, 126.8, 125.8, 122.9, 120.3, 118.9, 111.5, 109.5, 79.5, 63.1, 50.5, 36.6, 20.4; HRMS (ESI) Calcd. for C₂₆H₂₁N₂O₂ClNa, [M+Na]⁺ 451.1184. Found: 451.1183.

Chiral HPLC analysis of racemic **2d**.



PDA Ch2 220nm 4nm					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	11.216	124240103	1943274	46.205	62.909
2	18.164	144645931	1145767	53.795	37.091
Total		268886034	3089041	100.000	100.000


Chiral HPLC analysis of **2d** from asymmetric reaction.




(2*S*,11*bS*)-2-hydroxy-11*b*-(4-nitrophenyl)-2-phenyl-1,2,5,6,11,11*b*-hexahydro-3*H*-indolizino[8,7-*b*]indol-3-one (2e)**

White solid (63 mg, 71% yield). m.p. 182-183 °C; $[\alpha]_{25}^D = 64.7^\circ$ ($c = 0.5$, CHCl₃); ee = 99% (DAICEL Chiralpak AS-H, hexane/2-propanol = 70/30, $\lambda = 254$ nm, flow rate = 0.5 mL/min); IR (KBr) ν 3304, 3059, 1683, 1520, 1350 cm⁻¹; ¹H NMR (400MHz, DMSO-*d*₆, TMS) δ (ppm) 11.59 (s, 1H), 8.18 (d, *J* = 8.4 Hz, 2H), 7.66 (d, *J* = 8.8 Hz, 2H), 7.46-7.40 (m, 4H), 7.32 (t, *J* = 7.6 Hz, 2H), 7.27-7.23 (m, 1H), 7.18-7.14 (m, 1H), 7.03 (t, *J* = 7.2 Hz, 1H), 6.15 (s, 1H), 4.41-4.36 (m, 1H), 3.20 (d, *J* = 14.0 Hz, 1H), 3.10-3.02 (m, 1H), 2.96-2.88 (m, 1H), 2.77-2.69 (m, 2H); ¹³C NMR (100MHz, DMSO-*d*₆, TMS) δ (ppm) 174.8, 151.1, 146.6, 143.1, 136.3, 134.9, 128.0, 127.4, 127.3, 126.2, 125.8, 123.8, 121.7, 119.0, 118.2, 111.5, 106.9, 78.1, 62.7, 51.3, 36.5, 19.8; HRMS (ESI) Calcd. for C₂₆H₂₁N₃O₄Na, [M+Na]⁺ 462.1424. Found: 462.1423.

Chiral HPLC analysis of racemic **2e**.



Chiral HPLC analysis of **2e** from asymmetric reaction.




(2*S*,11*b**S*)-11*b*-{(3-bromophenyl)-2-hydroxy-2-phenyl-1,2,5,6,11,11*b*-hexahydro-3*H*-indolizino[8,7-*b*]indol-3-one (**2f**)


White solid (82 mg, 86% yield). m.p. 143-146 °C; $[\alpha]_{25}^D = 115.3^\circ$ ($c = 0.5$, CHCl₃); ee = 99% (DAICEL Chiralpak AS-H, hexane/2-propanol = 70/30, $\lambda = 254$ nm, flow rate = 0.5 mL/min); IR (KBr) ν 3301, 1681, 1661, 1446, 1418 cm⁻¹; ¹H NMR (400MHz, DMSO-*d*₆, TMS) δ (ppm) 11.50 (s, 1H), 7.47-7.24 (m, 11H), 7.14 (t, *J* = 7.8 Hz, 1H), 7.03 (t, *J* = 7.6 Hz, 1H), 6.08 (s, 1H), 4.35-4.32 (m, 1H), 3.12 (d, *J* = 13.8 Hz, 1H),

3.07-3.00 (m, 1H), 2.94-2.85 (m, 1H), 2.76-2.70 (m, 2H); ^{13}C NMR (100MHz, DMSO-*d*₆, TMS) δ (ppm) 174.3, 146.2, 143.0, 135.9, 135.2, 130.6, 130.1, 128.5, 127.7, 127.1, 125.9, 125.6, 124.6, 121.6, 121.3, 118.6, 117.9, 111.1, 106.3, 77.8, 62.1, 51.2, 36.0, 19.6; HRMS (ESI) Calcd. for C₂₆H₂₀N₂O₂Br, [M-H]⁺ 473.0688. Found: 473.0684.

Chiral HPLC analysis of racemic **2f**.




Chiral HPLC analysis of **2f** from asymmetric reaction.



(2S,11bS)-2-hydroxy-11b-(3-methoxyphenyl)-2-phenyl-1,2,5,6,11,11b-hexahydro-3H-indolizino[8,7-b]indol-3-one (2g)


White solid (71 mg, 83% yield). m.p. 146-148 °C; $[\alpha]_{25}^D = 80.0^\circ$ ($c = 0.5$, CHCl₃); ee = 98% (DAICEL Chiralpak AS-H, hexane/2-propanol = 70/30, $\lambda = 254$ nm, flow rate = 0.5 mL/min); IR (KBr) ν 3331, 3058, 2937, 2847, 1655, 1600, 1492, 1446, 1262 cm⁻¹; ¹H NMR (400MHz, DMSO-*d*₆, TMS) δ (ppm) 11.45 (s, 1H), 7.44-7.40 (m, 4H), 7.35-7.32 (m, 2H), 7.28-7.23 (m, 2H), 7.15-7.11 (m, 1H), 7.04-7.00 (m, 1H), 7.89-7.78 (m, 3H), 6.05 (s, 1H), 5.76 (s, 1H), 4.34-4.30 (m, 1H), 3.15-3.02 (m, 2H), 2.95-2.86 (m, 1H), 2.78-2.68 (m, 2H); ¹³C NMR (100MHz, DMSO-*d*₆, TMS) δ (ppm) 174.5, 159.3, 145.6, 143.8, 136.2, 136.1, 129.7, 128.0, 127.3, 126.2, 125.8, 121.4, 118.8, 118.1, 112.4, 112.2, 111.3, 106.3, 78.2, 62.7, 55.0, 51.6, 36.2, 19.9; HRMS (ESI) Calcd. for C₂₇H₂₄N₂O₃Na, [M+Na]⁺ 447.1679. Found: 447.1681.

Chiral HPLC analysis of racemic **2g**.



PDA Ch1 254nm 4nm					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	12.983	14495471	236841	49.795	80.098
2	33.112	14614569	58848	50.205	19.902
Total		29110039	295689	100.000	100.000


Chiral HPLC analysis of **2g** from asymmetric reaction.



(2*S*,11*bS*)-2-(3-bromophenyl)-11*b*-(4-bromophenyl)-2-hydroxy-1,2,5,6,11,11*b*-hexahydro-3*H*-indolizino[8,7-*b*]indol-3-one (2h)**


White solid (99 mg, 90% yield). m.p. 184-187 °C; $[\alpha]_{25}^D = 118.0^\circ$ ($c = 0.5$, CHCl₃); ee = 99.5% (DAICEL Chiraldpak AS-H, hexane/2-propanol = 70/30, $\lambda = 254$ nm, flow rate = 0.5 mL/min); IR (KBr) ν 3322, 1669, 1451, 1433, 1395 cm⁻¹; ¹H NMR (400MHz, DMSO-*d*₆, TMS) δ (ppm) 11.47 (s, 1H), 7.55-7.28 (m, 10H), 7.13 (t, *J* = 7.6 Hz, 1H), 7.02 (t, *J* = 7.3 Hz, 1H), 6.22 (s, 1H), 4.32-4.29 (m, 1H), 3.11 (d, *J* = 14.2 Hz, 1H), 3.07-3.00 (m, 1H), 2.93-2.84 (m, 1H), 2.74-2.68 (m, 2H); ¹³C NMR (100MHz, DMSO-*d*₆, TMS) δ (ppm) 174.0, 145.8, 143.0, 136.1, 135.5, 131.5, 130.31, 130.26, 128.7, 128.2, 126.2, 125.0, 121.5, 121.4, 120.8, 118.9, 118.2, 111.4, 106.4, 77.7, 62.5, 51.0, 36.4, 19.9; HRMS (ESI) Calcd. for C₂₆H₁₉N₂O₂Br₂, [M-H]⁺ 550.9793. Found: 550.9788.

Chiral HPLC analysis of racemic **2h**.



PeakTable					
PDA Ch2 220nm 4nm					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	11.448	58570125	819714	50.783	67.221
2	18.616	56763938	399710	49.217	32.779
Total		115334063	1219425	100.000	100.000

Chiral HPLC analysis of **2h** from asymmetric reaction.




峰表					
PDA Ch2 220nm 4nm					
峰#	保留时间	面积	高度	面积 %	高度 %
1	11.361	71639672	1026415	99.735	99.805
2	17.979	190415	2003	0.265	0.195
Total		71830087	1028418	100.000	100.000

(2*S*,11*b**S*)-2,11*b*-bis(4-bromophenyl)-2-hydroxy-1,2,5,6,11,11*b*-hexahydro-3*H*-indolizino[8,7-*b*]indol-3-one (**2i**)


White solid (98 mg, 89% yield). m.p. 286-288 °C; $[\alpha]_{25}^D = 145.3^\circ$ ($c = 0.5$, CHCl₃); ee = 97% (DAICEL Chiraldak AS-H, hexane/2-propanol = 70/30, $\lambda = 254$ nm, flow rate = 0.5 mL/min); IR (KBr) ν 3256, 1678, 1487, 1442, 1426, 1395 cm⁻¹; ¹H NMR (400MHz, DMSO-*d*₆, TMS) δ (ppm) 11.46 (s, 1H), 7.53 (d, *J* = 6.9 Hz, 4H), 7.42 (t, *J* = 7.8 Hz, 2H), 7.34 (d, *J* = 8.7 Hz, 2H), 7.25 (d, *J* = 8.7 Hz, 2H), 7.13 (t, *J* = 7.6 Hz,

1H), 7.02 (t, J = 7.6 Hz, 1H), 6.17 (s, 1H), 4.30-4.27 (m, 1H), 3.13 (d, J = 14.2 Hz, 1H), 3.02-2.96 (m, 1H), 2.93-2.86 (m, 1H), 2.72-2.66 (m, 2H); ^{13}C NMR (100MHz, DMSO-*d*₆, TMS) δ (ppm) 174.3, 143.2, 142.8, 136.1, 135.5, 131.5, 130.9, 128.3, 128.2, 126.3, 121.5, 120.8, 120.6, 118.9, 118.2, 111.4, 106.5, 77.9, 62.6, 51.1, 36.4, 19.9; HRMS (ESI) Calcd. for C₂₆H₁₉N₂O₂Br₂, [M-H]⁺ 550.9793. Found: 550.9788.

Chiral HPLC analysis of racemic **2i**.



Chiral HPLC analysis of **2i** from asymmetric reaction.




(2*S*,11*bS*)-11*b*-(4-bromophenyl)-2-hydroxy-2-(p-tolyl)-1,2,5,6,11,11*b*-hexahydro-3**


H-indolizino[8,7-*b*]indol-3-one (2j)

White solid (88 mg, 90% yield). m.p. 272-274 °C; $[\alpha]_{25}^D = 151.3^\circ$ ($c = 0.5$, CHCl₃); ee = 92% (DAICEL Chiralpak AS-H, hexane/2-propanol = 70/30, $\lambda = 254$ nm, flow rate = 0.5 mL/min); IR (KBr) ν 3358, 3271, 1680, 1441, 1422 cm⁻¹; ¹H NMR (400MHz, DMSO-*d*₆, TMS) δ (ppm) 11.45 (s, 1H), 7.52 (d, $J = 8.3$ Hz, 2H), 7.42 (t, $J = 6.6$ Hz, 2H), 7.26 (t, $J = 9.2$ Hz, 4H), 7.15-7.11 (m, 3H), 7.02 (t, $J = 7.6$ Hz, 1H), 5.98 (s, 1H), 4.32-4.27 (m, 1H), 3.13 (d, $J = 14.2$ Hz, 2H), 3.01-2.96 (m, 1H), 2.93-2.86 (m, 1H), 2.68 (d, $J = 13.7$ Hz, 2H), 2.28 (s, 3H); ¹³C NMR (100MHz, DMSO-*d*₆, TMS) δ (ppm) 174.8, 143.4, 140.6, 136.4, 136.1, 135.8, 131.5, 128.5, 128.2, 126.3, 125.7, 121.5, 120.7, 118.8, 118.1, 111.4, 106.5, 78.0, 62.4, 51.5, 36.2, 20.7, 19.9; HRMS (ESI) Calcd. for C₂₇H₂₂N₂O₂Br, [M-H]⁺ 485.0870. Found: 485.0863.

Chiral HPLC analysis of racemic 2j.




Chiral HPLC analysis of 2j from asymmetric reaction.




(2*S*,11*bS*)-11*b*-(4-bromophenyl)-8-chloro-2-hydroxy-2-phenyl-1,2,5,6,11,11*b*-hexa hydro-3*H*-indolizino[8,7-*b*]indol-3-one (2k)**

White solid (87 mg, 86% yield). m.p. 274-277 °C; $[\alpha]_{25}^D = 124.0^\circ$ ($c = 0.5$, CHCl₃); ee = 96% (DAICEL Chiralpak AS-H, hexane/2-propanol = 70/30, $\lambda = 254$ nm, flow rate = 0.5 mL/min); IR (KBr) ν 3364, 3267, 1686, 1488, 1446, 1428, 1397 cm⁻¹; ¹H NMR (400MHz, DMSO-*d*₆, TMS) δ (ppm) 11.71 (s, 1H), 7.53 (d, $J = 8.2$ Hz, 2H), 7.49 (d, $J = 1.8$ Hz, 1H), 7.44-7.39 (m, 3H), 7.34 (t, $J = 7.6$ Hz, 2H), 7.28- 7.24 (m, 3H), 7.15-7.12 (m, 1H), 6.08 (s, 1H), 4.30-4.26 (m, 1H), 3.14 (d, $J = 14.2$ Hz, 1H), 3.02-2.95 (m, 1H), 2.91-2.83 (m, 1H), 2.71-2.66 (m, 2H); ¹³C NMR (100MHz, DMSO-*d*₆, TMS) δ (ppm) 174.8, 143.4, 143.1, 137.5, 134.5, 131.6, 128.2, 128.0, 127.5, 127.3, 125.8, 123.5, 121.4, 120.8, 117.6, 112.9, 106.6, 78.1, 62.5, 51.4, 36.2, 19.7; HRMS (ESI) Calcd. for C₂₆H₁₉N₂O₂ClBr, [M-H]⁺ 507.0298. Found: 507.0290.

Chiral HPLC analysis of racemic **2k**.



Chiral HPLC analysis of **2k** from asymmetric reaction.




(*2S,11bS*)-*11b*-(4-bromophenyl)-2-hydroxy-8-methyl-2-phenyl-1,2,5,6,11,11*b*-hexahydro-3*H*-indolizino[8,7-*b*]indol-3-one (**2l**)

White solid (86 mg, 88% yield). m.p. 251-254 °C; $[\alpha]_{25}^D = 138.0^\circ$ ($c = 0.5$, CHCl₃); ee = 96% (DAICEL Chiralpak AS-H, hexane/2-propanol = 70/30, $\lambda = 254$ nm, flow rate = 0.5 mL/min); IR (KBr) ν 3406, 3286, 1710, 1679, 1440, 1447, 1412, 1396 cm⁻¹; ¹H NMR (400MHz, CDCl₃, TMS) δ (ppm) δ 8.13 (s, 1H), 7.45-7.42 (m, 2H), 7.34-7.29


(m, 6H), 7.23 (d, J = 8.7 Hz, 1H), 7.04 (d, J = 8.2 Hz, 1H), 6.94 (d, J = 8.7 Hz, 2H), 4.42-4.38 (m, 1H), 3.13-2.97 (m, 3H), 2.92 (d, J = 14.2 Hz, 1H), 2.72-2.67 (m, 1H), 2.46 (s, 3H); ^{13}C NMR (100MHz, CDCl_3 , TMS) δ (ppm) 174.6, 142.5, 141.8, 134.5, 134.4, 131.7, 129.6, 128.7, 128.5, 128.3, 126.9, 125.7, 124.3, 122.2, 118.5, 111.0, 109.0, 79.4, 63.1, 50.3, 36.5, 21.5, 20.2; HRMS (ESI) Calcd. for $\text{C}_{27}\text{H}_{22}\text{N}_2\text{O}_2\text{Br}$, $[\text{M}-\text{H}]^+$ 487.0844. Found: 487.0843.

Chiral HPLC analysis of racemic **2l**.



PeakTable					
PDA Ch1 254nm 4nm					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	10.514	7371805	142743	49.465	82.117
2	22.276	7531361	31086	50.535	17.883
Total		14903166	173829	100.000	100.000

Chiral HPLC analysis of **2l** from asymmetric reaction.




PeakTable					
PDA Ch1 254nm 4nm					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	10.341	14234773	269993	97.981	98.708
2	23.346	293285	3535	2.019	1.292
Total		14528058	273527	100.000	100.000


**(2S,11bS)-11b-(4-bromophenyl)-2-hydroxy-8-methoxy-2-phenyl-1,2,5,6,11,11b-he
xahydro-3H-indolizino[8,7-b]indol-3-one (2m)**

White solid (87 mg, 86% yield). m.p. 165-167 °C; $[\alpha]_{25}^D = 142.0^\circ$ ($c = 0.5$, CHCl₃); ee = 94% (DAICEL Chiralpak AS-H, hexane/2-propanol = 70/30, $\lambda = 254$ nm, flow rate = 0.5 mL/min); IR (KBr) ν 3406, 3310, 1693, 1677, 1487, 1436, 1401, 1217 cm⁻¹; ¹H NMR (400MHz, CDCl₃, TMS) δ (ppm) 11.29 (s, 1H), 7.52 (d, $J = 8.2$ Hz, 2H), 7.39 (d, $J = 6.9$ Hz, 2H), 7.35-7.24 (m, 6H), 6.93 (d, $J = 2.3$ Hz, 1H), 6.78- 6.76 (m, 1H), 6.05 (s, 1H), 4.31-4.28 (m, 1H), 3.76 (s, 3H), 3.13 (d, $J = 13.8$ Hz, 1H), 3.03-2.95 (m, 1H), 2.91-2.83 (m, 1H), 2.70-2.63 (m, 2H); ¹³C NMR (100MHz, CDCl₃, TMS) δ (ppm) 174.7, 153.4, 143.5, 143.4, 136.3, 131.5, 131.1, 128.2, 128.0, 127.3, 126.6, 125.8, 120.7, 112.0, 111.4, 106.3, 100.2, 78.2, 62.6, 55.4, 51.5, 36.3, 19.9; HRMS (ESI) Calcd. for C₂₇H₂₂N₂O₃Br, [M-H]⁺ 501.0819. Found: 501.0812.

Chiral HPLC analysis of racemic **2m**.




Chiral HPLC analysis of **2m** from asymmetric reaction.



6. Synthesis of 3, 4 and 5

6.1 Synthesis of 3




A mixture of **2b'** (94.7 mg, 0.2 mmol) and Burgess reagent (153.8 mg, 0.6 mmol) were refluxed in THF (5 mL) until raw materials disappeared about 20 min. Water was added to quench the reaction and the mixture was extracted with ethyl acetate (3×5 mL). The combined organic phases were dried over anhydrous Na_2SO_4 and concentrated in vacuo. Flash chromatography on silica gel (PE:EA = 2:1) afforded **3** as white solid.

(R)-11b-(4-bromophenyl)-2-phenyl-5,6,11,11b-tetrahydro-3*H*-indolizino[8,7-*b*]indol-3-one (3)

White solid (89 mg, 98% yield). m.p. 294-295 °C; $[\alpha]_{25}^D = -122.0^\circ$ ($c = 0.5$, CHCl_3); ee = -97% (DAICEL Chiralpak OD-H, hexane/2-propanol = 80/20, $\lambda = 254$ nm, flow rate = 0.5 mL/min); IR (KBr) ν 3230, 3060, 1664, 1485, 1403 cm^{-1} ; ^1H NMR


(400MHz, DMSO-*d*₆, TMS) δ (ppm) 11.51 (s, 1H), 7.97-7.93 (m, 3H), 7.60-7.57 (m, 2H), 7.50-7.37 (m, 5H), 7.17-7.10 (m, 3H), 7.06-7.02 (m, 1H), 4.40-4.36 (m, 1H), 3.03-2.95 (m, 1H), 2.86-2.77 (m, 1H); ¹³C NMR (100MHz, DMSO-*d*₆, TMS) δ (ppm) 168.9, 143.7, 138.2, 136.3, 134.0, 131.8, 131.5, 130.8, 129.1, 129.0, 128.6, 127.1, 126.0, 122.1, 121.7, 119.1, 118.7, 111.5, 107.9, 65.8, 35.0, 21.0; HRMS (ESI) Calcd. for C₂₆H₁₉N₂OBrNa, [M+Na]⁺ 477.0573. Found: 477.0572.

Chiral HPLC analysis of racemic **3**.




峰表					
PDA Ch1 254nm 4nm					
峰#	保留时间	面积	高度	面积 %	高度 %
1	13.815	61171762	1276598	49.345	58.866
2	20.152	62795865	892063	50.655	41.134
Total		123967627	2168661	100.000	100.000

Chiral HPLC analysis of **3** from asymmetric reaction.



6.2 Synthesis of 4




To a flask (10 mL) equipped with a magnetic stirrer was added LiAlH₄ (15.3 mg, 0.4 mmol), AlCl₃ (52.9 mg, 0.4 mmol), **2b'** (94.7 mg, 0.2 mmol) and dry THF (5 mL) under argon protection. The reaction mixture was stirred at room temperature for 2 h and then saturated NH₄Cl aqueous solution (0.2 mL) was added to quench the reaction. The mixture was extracted with ethyl acetate (3×10 mL), and combined organic layer was washed with brine and dried over anhydrous Na₂SO₄. The solvents were removed in *vacuo* and the residue was purified by flash column chromatography (PE:EA = 4:1) to afford products **4**.

(2*R*,11*b**R*)-11*b*-(4-bromophenyl)-2-phenyl-2,3,5,6,11,11*b*-hexahydro-1*H*-indolizino[8,7-*b*]indol-2-ol (**4**)

White solid (88 mg, 96% yield). m.p. 128-130 °C; [α]₂₅^D = 32.7° (c = 0.5, CHCl₃); ee = -96% (DAICEL Chiralpak OD-H, hexane/2-propanol = 80/20, λ = 254 nm, flow rate = 0.5 mL/min); IR (KBr) ν 3422, 3056, 2921, 2846, 1485, 1460, 1447, 1393 cm⁻¹;


¹H NMR (400MHz, ACETONE-D₆, TMS) δ (ppm) 10.34 (s, 1H), 7.76-7.74 (m, 2H), 7.50 (d, *J* = 8.0 Hz, 1H), 7.43-7.40 (m, 3H), 7.38-7.33 (m, 4H), 7.25-7.22 (m, 1H), 7.15-7.11 (m, 1H), 7.07-7.03 (m, 1H), 3.61 (d, *J* = 9.6 Hz, 1H), 3.47 (d, *J* = 9.6 Hz, 1H), 3.19 (dd, *J* = 13.6, 5.6 Hz, 1H), 3.11-3.06 (m, 2H), 2.96-2.86 (m, 2H), 2.63 (d, *J* = 14.0 Hz, 1H), 2.51 (dd, *J* = 15.6, 4.4 Hz, 1H); ¹³C NMR (100MHz, ACETONE-D₆, TMS) δ (ppm) 150.9, 147.1, 137.4, 136.2, 131.7, 130.2, 128.8, 128.4, 127.1, 125.7, 122.1, 121.0, 119.6, 119.0, 111.9, 108.3, 79.6, 68.1, 65.9, 59.4, 41.7, 16.7; HRMS (ESI) Calcd. for C₂₆H₂₄N₂OBr, [M+H]⁺ 459.1067. Found: 459.1063.

Chiral HPLC analysis of racemic **4**.



峰表					
PDA Ch1 254nm 4nm					
峰#	保留时间	面积	高度	面积 %	高度 %
1	11.755	13631891	450569	49.721	68.439
2	24.392	13784753	207786	50.279	31.561
Total		27416644	658355	100.000	100.000


Chiral HPLC analysis of **4** from asymmetric reaction.



峰表

PDA Ch1 254nm 4nm					
峰#	保留时间	面积	高度	面积 %	高度 %
1	11.710	943045	29672	2.016	4.811
2	25.133	45832504	587044	97.984	95.189
Total		46775549	616716	100.000	100.000

6.3 Synthesis of 5




To a mixture of **2b'** (94.7 mg, 0.2 mmol) and dry acetone (5 mL) in flask was added NBS (39.2 mg, 0.22 mmol) in part. The mixture was kept stirring at room temperature until raw materials disappeared about 10 min. The residue was concentrated and purified by flash column chromatography on silica gel (PE:EA = 4:1) to give product **5**.

(2*R*,6*aR*,11*bR*)-6*a*-bromo-11*b*-(4-bromophenyl)-2-hydroxy-2-phenyl-1,2,5,6,6*a*,11*b*-hexahydro-3*H*-indolizino[8,7-*b*]indol-3-one (**5**)


White solid (101 mg, 92% yield). m.p. 187-189 °C; $[\alpha]_{25}^D = 76.0^\circ$ ($c = 0.5$, CHCl₃); ee = -97.5% (DAICEL Chiralpak OD-H, hexane/2-propanol = 80/20, $\lambda = 254$ nm, flow rate = 0.5 mL/min); IR (KBr) ν 3431, 1688, 1424, 1256 cm⁻¹; ¹H NMR (400MHz, CDCl₃, TMS) δ (ppm) 7.75 (d, $J = 7.6$ Hz, 1H), 7.48-7.40 (m, 4H), 7.37-7.32 (m, 3H), 7.28-7.23 (m, 3H), 7.21-7.18 (m, 2H), 4.58-4.53 (m, 1H), 3.93 (d, $J = 14.0$ Hz, 1H), 3.66-3.59 (m, 1H), 2.75-2.66 (m, 2H), 1.91-1.83 (m, 1H); ¹³C NMR (100MHz,

DMSO-*d*₆, TMS) δ (ppm) 181.3, 173.9, 152.1, 143.2, 141.4, 140.2, 131.4, 129.3, 127.8, 127.3, 127.0, 126.6, 125.8, 122.7, 121.1, 120.2, 80.7, 77.1, 65.8, 48.9, 38.2, 34.1; HRMS (ESI) Calcd. for C₂₆H₂₀N₂O₂Br₂Na, [M+Na]⁺ 572.9784. Found: 572.9783.

Chiral HPLC analysis of racemic **5**.



Chiral HPLC analysis of **5** from asymmetric reaction.



7. The X-ray molecular structure of compounds (2S, 11bS)-2b




Figure S2. The structure of compound **2b**

7.1 Crystallographic data and structure refinement of (2S, 11bS)-2b

Identification code	xxm-02
Empirical formula	C ₃₀ H ₂₉ BrN ₂ O ₄
Formula weight	561.46
Temperature	173.00(10) K
Wavelength	1.54184 Å
Crystal system	Monoclinic
Space group	P 1 21 1
Unit cell dimen	a = 9.9350 (2) Å α = 90.00 ° b = 12.0944 (2) Å β = 110.004 (2)° c = 12.1297 (2) Å γ = 90.00 °
Volumn	1369.55 (5) Å ³
Z	2
Crystal size	0.15 x 0.11 x 0.08 mm ³
CCDC Number	2026743

8. References

- [1] (a) L. Yang, D.-X. Wang, Z.-T. Huang and M.-X. Wang, *J. Am. Chem. Soc.* **2009**, *131*, 10390. (b) S. Tong, D.-X. Wang, L. Zhao, J. Zhu, M.-X. Wang, *Angew. Chem. Int. Ed.* **2012**, *51*, 4417; *Angew. Chem.* **2012**, *124*, 4493.
[2] (a) L. He, L. Zhao, D.-X. Wang, M.-X. Wang, *Org. Lett.* **2014**, *16*, 5972.(ba) S. Tong, X. Yang, D.-X. Wang, L. Zhao, J. Zhu, M.-X. Wang, *Tetrahedron* **2012**, *68*, 6492. (c) L. Yang, G. Deng, D.-X. Wang, Z.-T. Huang, J. Zhu, M.-X. Wang, *Org. Lett.* **2007**, *9*, 1387.

9. Copies of ^1H NMR and ^{13}C NMR Spectra of Products

